ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Kiniksa Pharmaceuticals International PLC

Kiniksa Pharmaceuticals International PLC (KNSA)

51,96
0,38
( 0,74% )
Aktualisiert: 18:03:56

Kiniksa Pharmaceuticals International PLC (KNSA) Aktie

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Premium

Wichtige Statistiken und Details

Current Price
51,96
( 0,74% )
Gebot
51,85
Fragen
52,02
Volumen
105.778
51,36 Tagesbereich 52,48
26,27 52-Wochen-Bereich 59,87
Marktkapitalisierung
Handelsende
51,58
Handelsbeginn
51,66
Letzte Trade
1
@
51.969
Letzter Handelszeitpunkt
18:04:41
Finanzvolumen
US$ 5.492.985
VWAP
51,9294
Durchschnittliches Volumen (3 Mio.)
US$ 671.657
Ausgegebene Aktien
76.938.016
Dividendenrendite (LTM)
Kurs-Gewinn-Verhältnis
53,65
Gewinn pro Aktie (EPS)
0,91
Erlöse (LTM)
754,05M
Nettogewinn (LTM)
73,06M

Über Kiniksa Pharmaceuticals International PLC

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis... Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom. Mehr anzeigen

Sektor
Healthcare
Branche
Biotechnology & Life Sciences
Website
Hauptsitz
London, United Kingdom
Gegründet
2026
Kiniksa Pharmaceuticals International PLC is listed in the Healthcare sector of the NASDAQ with ticker KNSA. The last closing price for Kiniksa Pharmaceuticals was US$51,58. Over the last year, Kiniksa Pharmaceuticals shares have traded in a share price range of US$ 26,27 to US$ 59,87.

Kiniksa Pharmaceuticals currently has 76.938.016 shares in issue. The market capitalisation of Kiniksa Pharmaceuticals is US$4,00 billion. Kiniksa Pharmaceuticals has a price to earnings ratio (PE ratio) of 53.65.

KNSA Neueste Nachrichten

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
12.986.084115965748.9852.4847.9547957249.58240772CS
4-6.04-10.41379310345858.5646.100453843950.87687666CS
126.4614.197802197845.559.8741.4966667749.85521667CS
2610.926.546517291841.0659.8737.0264047046.64475291CS
5221.7571.996027805430.2159.8726.2760971940.25263949CS
15636.95246.1692205215.0159.8713.5651241628.41590166CS
26036.96246.41559.877.3645678323.18295889CS

KNSA - Frequently Asked Questions (FAQ)

What is the current Kiniksa Pharmaceuticals International PLC share price?
The current share price of Kiniksa Pharmaceuticals International PLC is US$ 51,96
How many Kiniksa Pharmaceuticals International PLC shares are in issue?
Kiniksa Pharmaceuticals International PLC has 76.938.016 shares in issue
What is the market cap of Kiniksa Pharmaceuticals International PLC?
The market capitalisation of Kiniksa Pharmaceuticals International PLC is USD 4B
What is the 1 year trading range for Kiniksa Pharmaceuticals International PLC share price?
Kiniksa Pharmaceuticals International PLC has traded in the range of US$ 26,27 to US$ 59,87 during the past year
What is the PE ratio of Kiniksa Pharmaceuticals International PLC?
The price to earnings ratio of Kiniksa Pharmaceuticals International PLC is 53,65
What is the cash to sales ratio of Kiniksa Pharmaceuticals International PLC?
The cash to sales ratio of Kiniksa Pharmaceuticals International PLC is 4,97
What is the registered address of Kiniksa Pharmaceuticals International PLC?
The registered address for Kiniksa Pharmaceuticals International PLC is 105 Piccadilly, London, Greater London, W1J 7NJ
What is the Kiniksa Pharmaceuticals International PLC website address?
The website address for Kiniksa Pharmaceuticals International PLC is www.kiniksa.com
Which industry sector does Kiniksa Pharmaceuticals International PLC operate in?
Kiniksa Pharmaceuticals International PLC operates in the Biotechnology & Life Sciences sector

KNSA Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen